SCLC

This page shows the latest SCLC news and features for those working in and with pharma, biotech and healthcare.

Imfinzi aces survival challenge in lung cancer

second-line head and neck cancer, small cell lung cancer (SCLC) and bladder cancer.

Latest news

FDA green lights BMS’ Opdivo for ‘hard-to-treat’ small cell lung cancer

The treatment, which was approved on Friday, has claimed the title of the first and only immuno-oncology treatment for SCLC patients who have received platinum chemo and at least one ... This ‘hard-to-treat’disease accounts for up to 15% of all lung
Pivotal data sets up Tecentriq filing in small cell lung cancer

Tecentriq (atezolizumab) as a front-line therapy in combination with chemotherapy for ES-SCLC. ... Typically, 5% or less of ES-SCLC patients – in whom the tumour has spready beyond the lung and adjacent lymph nodes – are still alive after five years.
AbbVie slumps on trial results for would-be blockbuster Rova-T

potential while moving swiftly ahead with additional trials in both second-line (TAHOE) and first-line SCLC (MERU). ... and remain committed to developing Rova-T for the treatment of patients with SCLC.".
Biotecnol taps into Cancer Research UK network for first trial

despite treatment, particularly mesothelioma, small-cell lung carcinoma (SCLC) and non-small cell lung cancer (NSCLC), and renal cell carcinoma.
AbbVie's PARP inhibitor veliparib fails to deliver

Rova-T for small cell lung cancer (SCLC) and ABT-414 for the brain cancer glioblastoma.

More from news
Approximately 3 fully matching, plus 13 partially matching documents found.

Latest Intelligence

Deal Watch February 2017

triple-negative breast cancer (TNBC), small-cell lung cancer (SCLC), non-small-cell lung cancer (NSCLC) and pancreatic cancer.
Deal Watch April 2016

Rova-T showed a 44% overall response rate in DLL-expressing small cell lung cancer (SCLC) patients who had failed one or more standard therapies.
Deal Watch November 2015

July finalised a $730m exclusive deal with Boehringer Ingelheim for HM61713, an orally active third generation EGFR agent in small cell lung cancer (SCLC).

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

New Business Director - PR: Competitive Salary and benefits

Account Manager, Healthcare Public Affairs: £32, 000 – £40, 000 benefits

Associate Editorial Director – Med Comms – London: Salary TBC

Account Director: Excellent benefits

Programme Director, Healthcare PR, Highly competitive package: Highly Competitive package

Medical/ Scientific Director: Salary TBC

Medical Writers Required – Cheshire: DOE

Director, Market Access / HEOR - North-West: Negotiable

Associate Medical Director: Highly Competitive

Events Manager – Med Comms – Surrey: Salary TBC

Senior Account Manager: Negotiable

Freelance Account Manager / Senior Account Manager - Medical Edu...: £300 per day

Chief Medical Writer, Medical Communications, London, up to £90K...: up to £90K

Production Manager – Healthcare Communications: DOE

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

Senior Medical Writer (Remote Working): Competitive Salary Offered

Associate Director: £75, 000-90, 000

Digital Manager, London – Healthcare Brandcomms, Medcomms, PR: Excellent package

Senior Medical Writer: Competitive Salary

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

Medical Writers: Competitive Salary and Benefits

Medical Writer – Health Behaviour/ Patient Adherence Agency: Salary TBC

Senior Medical Writer: Great salary and benefits

Scientific Director / Editorial Team Leader: Great salary and benefits

SAM – Health Behaviour/ Patient Adherence Healthcare Agency: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

World Diabetes Day: Interaction and impact of diabetes on mental health: For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
Innovation in merger control and the impact on the pharmaceutical sector: Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think: Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...